Skip to main content

Advertisement

Table 8 Composite endpoints

From: Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study

  Arm A Arm B Arm C
  n n n
DVT proximal 0 0 0
DVT distal 0 0 2
PE 0 0 0
Death on study 0 0 0
Exact Odds Ratios
Unadjusted Estimate 95 % Confidence Limits p-value
Odds Ratio (median unbiased)   
Arm A vs. Arm C 0.397 0 – 3.344 0.480
Arm B vs. Arm C 0.387 0 - 3.259 0.476
Noninferiority Analysis of Risk Difference
Risk Difference Estimate 95 % Confidence Limits p-value*
Arm C vs. Arm A −0.0180 −0.0428 – 0.0067 <0.0001
Arm C vs. Arm B −0.0180 −0.0428 – 0.0067 <0.0001
  1. *Using a noninferiority limit of -0.015